Ventria Bioscience Announces Third Bioprocessing Product: Cellastim™, Animal-Free Recombinant Human Serum Albumin

Share Article

This press release announces a new bioprocessing product for Ventria Bioscience called Cellastim. Cellastim is recombinant human serum albumin for use in cell culture.

Ventria Bioscience announces the introduction of Cellastim™, an animal-free recombinant Human Serum Albumin. This product will be introduced at the Raw Materials & Disposable Process Systems for Mammalian Cell Culture Conference hosted by the Williamsburg BioProcessing Foundation in Pasadena, California, on July 17th. The presentation titled “Animal-Free Recombinant Human Serum Albumin from Plants, Supports Cell Growth and Media Development” will be given by Steve Pettit, Ph.D., Medical Biochemist, Ventria Bioscience.

“I am pleased to introduce Cellastim™ to the biopharmaceutical industry at this conference. The presentation next week will describe Cellastim™’s clear advantage,” said Steve Pettit, Ph.D., Medical Biochemist, Ventria Bioscience. “Our data demonstrates that Cellastim™ supports cell growth and productivity in cell culture media equivalent or better than native Human Serum Albumin.”

“Cellastim™ represents an important milestone and the third product in Ventria’s bioprocessing product portfolio consisting of animal-free components for our bioprocessing customers,” said Scott Deeter, President and CEO, Ventria Bioscience. “And with its improved safety profile, it further demonstrates Ventria’s commitment to developing safe and innovative products.”

About Cellastim™

Cellastim™ is recombinant human serum albumin derived from plants using Ventria’s proprietary recombinant protein production system called ExpressTec™. ExpressTec™ is highly efficient and has an excellent safety profile. ExpressTec™ utilizes a GRAS (“Generally Recognized As Safe”) host and products from ExpressTec™ have been determined GRAS as medical food ingredients.

Cellastim™ holds many advantages over current alternatives including:

  • Improved Safety Profile

Cellastim™ eliminates the risk of contamination from Adventitious Viral Agents (AVAs) or Transmissible Spongiform Encephalopathies (TSEs, including BSE).

  • Saves Regulatory Time and Money

Cellastim™ is a completely animal-free product produced in a completely animal free system. The production process does not use any animal derived materials in any direct or indirect expression or purification steps, thus simplifying and expediting the FDA review process.

  • Substitutes Directly for Native Human Serum Albumin and Bovine Serum Albumin in Animal-Free Cell Culture Media

Cellastim™ performs equal to or better than native Human Serum Albumin in cell growth and monoclonal antibody production.

  • Consistent Performance

Cellastim™ has greater product definition and is well suited for chemically-defined media since it has less genetic variation which is common in native Human Serum Albumin

  • Cost-Effective

Cellastim™ is cost effective in animal-free industrial cell culture applications.

For more information about Cellastim, please go to

About Ventria Bioscience

Ventria has launched two other products for use in bioprocessing. Lacromin™ is an animal-free replacement for animal-derived transferrin that has been shown to improve productivity for mammalian cell culture media. More information about Lacromin™ is available at and pricing is available upon request. Lysobac™ is an animal-free lysing agent to improve recombinant protein yields from E. coli. More information is available at and pricing is available upon request.

To request a price quote for Lacromin™, Lysobac™ or Cellastim™, please contact Brandy Sargent at (916) 921-6148 ext. 27 or e-mail.

Statements in this announcement other than historical data and information constitute forward looking statements that involve risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements. Potential risks and uncertainties may include, but are not limited to, recent changes in senior management, fluctuations in operating results, market conditions and changes in technology and increased competition.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Brandy Sargent
Ventria Bioscience
916-921-6148 ext. 27
Email >
Visit website